Hyperion has reached an agreement with FDA (under the Special Protocol Assessment process) for the pivotal phase-III trial of investigational product HPN-100 (glycerol phenylbutyrate) in adults with urea
Rexahn, a clinical stage biopharmaceutical company developing oncology and CNS therapeutics, has completed patient enrollment in its phase-IIa clinical trial. The study is to evaluate the effectiveness of
ARYx has announced the results from phase 2/3 clinical trial, EmbraceAC, comparing anticoagulant agent tecarfarin (ATI-5923) with oral anticoagulant warfarin. In the trial, tecarfarin demonstrated efficacy essentially the
CanBas and Takeda, along with Takeda Oncology, have initiated the phase-II clinical trials of CBP501, for the treatment of patients with non-small cell lung cancer (NSCLC). Data from
sNDA has granted approval for Astellas’ moderately/severely refractory ulcerative colitis, as additional indication for the immunosuppressant Prograf (tacrolimus hydrate). The company had submitted a sNDA to the Pharmaceuticals
Diabetica Research Solutions (DRS) has introduced drsi Restore! Energy, which reportedly helps diabetics and pre-diabetics to experience balanced energy and stamina. The company said that drsi is
Access’ preclinical data has demonstrated that thiarabine shows efficacy in the prevention and treatment of rheumatoid arthritis (RA). In a well-established animal model for RA, a good restoration
Press Ganey, a health care improvement firm, is all set to open an office just outside Boston, to house its growing information technology and PatientFlow teams. The new
Presidio has selected one of the lead compounds in their hepatitis C virus (HCV) NS5A program to advance toward clinical development. The selected Presidio NS5A inhibitor, PPI-461, exhibits
Lexicon has initiated the phase-II clinical trial of LX1032, an oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. LX1032 is designed to reduce serotonin production
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.